HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of cancers in combination with other immunotherapies HTL0039732, was found to be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback